Tags

Type your tag names separated by a space and hit enter

Menopausal hormone therapy and risk of clinical breast cancer subtypes.
Cancer Epidemiol Biomarkers Prev. 2009 Apr; 18(4):1188-96.CE

Abstract

BACKGROUND

Breast cancer is a heterogeneous disease with subtypes that may vary in their etiologies. Menopausal hormone therapy has been associated more strongly with lobular and tubular than ductal histologic types and with tumors that are smaller, hormone receptor-positive, and of lower grade. At the same time, correlations have been observed between histology and clinical characteristics. To identify those tumor subtypes most strongly associated with hormone therapy use, it is necessary to disentangle these interrelationships.

METHODS

Based on 3,464 postmenopausal breast cancer cases and 6,657 controls from the population-based Mammary carcinoma Risk factor Investigation study, we used polytomous logistic regression to evaluate associations between hormone therapy use and risk of invasive breast cancer subtypes. We assessed variations in risk for selected tumor characteristics among histologic and hormone receptor subtypes, both overall and for specific hormone therapy regimens.

RESULTS

Lobular and mixed types showed less variation by prognostic factors than did ductal tumors. Current hormone therapy use had the strongest associations with prognostic variables in estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive ductal tumors and in lobular tumors regardless of ER/PR status, with little effect on ER/PR-negative ductal tumors. The observed associations varied minimally by hormone therapy type or regimen.

CONCLUSION

Current hormone therapy use was associated with more favorable breast cancer characteristics for ductal tumors but had less effect on prognostic characteristics in women with lobular tumors. Both histologic type and estrogen receptor/progesterone receptor status seem to be important in explaining the role of hormone therapy in the etiology of breast cancer subtypes.

Authors+Show Affiliations

Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany. t.slanger@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19336542

Citation

Slanger, Tracy E., et al. "Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 18, no. 4, 2009, pp. 1188-96.
Slanger TE, Chang-Claude JC, Obi N, et al. Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1188-96.
Slanger, T. E., Chang-Claude, J. C., Obi, N., Kropp, S., Berger, J., Vettorazzi, E., Braendle, W., Bastert, G., Hentschel, S., & Flesch-Janys, D. (2009). Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 18(4), 1188-96. https://doi.org/10.1158/1055-9965.EPI-09-0002
Slanger TE, et al. Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1188-96. PubMed PMID: 19336542.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Menopausal hormone therapy and risk of clinical breast cancer subtypes. AU - Slanger,Tracy E, AU - Chang-Claude,Jenny C, AU - Obi,Nadia, AU - Kropp,Silke, AU - Berger,Jürgen, AU - Vettorazzi,Eik, AU - Braendle,Wilhelm, AU - Bastert,Gunter, AU - Hentschel,Stefan, AU - Flesch-Janys,Dieter, Y1 - 2009/03/31/ PY - 2009/4/2/entrez PY - 2009/4/2/pubmed PY - 2009/6/17/medline SP - 1188 EP - 96 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 18 IS - 4 N2 - BACKGROUND: Breast cancer is a heterogeneous disease with subtypes that may vary in their etiologies. Menopausal hormone therapy has been associated more strongly with lobular and tubular than ductal histologic types and with tumors that are smaller, hormone receptor-positive, and of lower grade. At the same time, correlations have been observed between histology and clinical characteristics. To identify those tumor subtypes most strongly associated with hormone therapy use, it is necessary to disentangle these interrelationships. METHODS: Based on 3,464 postmenopausal breast cancer cases and 6,657 controls from the population-based Mammary carcinoma Risk factor Investigation study, we used polytomous logistic regression to evaluate associations between hormone therapy use and risk of invasive breast cancer subtypes. We assessed variations in risk for selected tumor characteristics among histologic and hormone receptor subtypes, both overall and for specific hormone therapy regimens. RESULTS: Lobular and mixed types showed less variation by prognostic factors than did ductal tumors. Current hormone therapy use had the strongest associations with prognostic variables in estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive ductal tumors and in lobular tumors regardless of ER/PR status, with little effect on ER/PR-negative ductal tumors. The observed associations varied minimally by hormone therapy type or regimen. CONCLUSION: Current hormone therapy use was associated with more favorable breast cancer characteristics for ductal tumors but had less effect on prognostic characteristics in women with lobular tumors. Both histologic type and estrogen receptor/progesterone receptor status seem to be important in explaining the role of hormone therapy in the etiology of breast cancer subtypes. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/19336542/Menopausal_hormone_therapy_and_risk_of_clinical_breast_cancer_subtypes_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=19336542 DB - PRIME DP - Unbound Medicine ER -